An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

Vaccine. 2007 Jan 8;25(4):741-50. doi: 10.1016/j.vaccine.2006.08.010. Epub 2006 Aug 22.

Abstract

We have developed recombinant vesicular stomatitis virus (VSV) vectors expressing the Yersinia pestis lcrV gene. These vectors, given intranasally to mice, induced high antibody titers to the LcrV protein and protected against intranasal (pulmonary) challenge with Y. pestis. High-level protection was dependent on using an optimized VSV vector that expressed high levels of the LcrV protein from an lcrV gene placed in the first position in the VSV genome, followed by a single boost. This VSV-based vaccine vector system has potential as a plague vaccine protecting against virulent strains lacking the F1 protein.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Intranasal
  • Animals
  • Female
  • Immunization, Secondary
  • Mice
  • Mice, Inbred BALB C
  • Plague / prevention & control*
  • Plague Vaccine / administration & dosage
  • Plague Vaccine / immunology*
  • Time Factors
  • Vesicular stomatitis Indiana virus / genetics*
  • Yersinia pestis / immunology*

Substances

  • Plague Vaccine